C5 and paroxysmal nocturnal hemoglobinuria: Tesidolumab, a humanized IgG1/λ anti-C5 monoclonal antibody, was tested on PNH patients with and without a C5 polymorphism, demonstrating effectiveness and safety [6], but no further data are available.